Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study

Ravina, B.; Puff, M.; Siderowf, A.; Farrar, J. T.; Gillespie, M.; Crawley, A.; Fernandez, H. H.; Trieschmann, M. M.; Reichwein, S.; Simuni, T.
July 2005
Journal of Neurology, Neurosurgery & Psychiatry;Jul2005, Vol. 76 Issue 7, p934
Academic Journal
Objective: To study the safely and efficacy of a cholinesterase inhibitor, donepezil hydrochloride, for the treatment of dementia in Parkinson's disease (PD). Methods: This was a randomised double blind, placebo controlled, crossover study in 22 subjects with PD and dementia. Participants were randomised to receive either donepezil followed by identical placebo, or placebo followed by donepezil. Donepezil was administered at 5-10 mg/day. Treatment periods were 10 weeks with a washout period of 6 weeks between the two periods. The primary outcome measure was the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAScog). Results: Donepezil was well tolerated and most adverse events were mild. There was no worsening of PD symptoms as measured by the total or motor sections of the Unified Parkinson's Disease Rating Scale. There was a 1.9 point trend toward better scores on the ADAScog on treatment compared with placebo that was not statistically significant. The secondary cognitive measures showed a statistically significant 2 point benefit on the Mini Mental Status Examination and no change on the Mattis Dementia Rating Scale (MDRS). The Clinical Global Impression of Change (CGI) showed a significant 0.37 point improvement on donepezil. No improvement was observed on the MDRS or the Brief Psychiatric Rating Scale. Carryover between treatment periods was observed but was not statistically significant. Conclusions: Donepezil was well tolerated and did not worsen PD. There may be a modest benefit on aspects of cognitive function. The possible clinical benefit measured by CGI was reflected in only one of the cognitive scales used in this study.


Related Articles

  • Cholinesterase Inhibitors as Adjunctive Therapy in Patients with Schizophrenia and Schizoaffective Disorder. Ribeiz, Salma R. I.; Bassitt, Débora P.; Arrais, Jony A.; Avila, Renata; Steffens, David C.; Bottino, Cássio M. C. // CNS Drugs;2010, Vol. 24 Issue 4, p303 

    Background: Cognitive deficits have been described in patients with schizophrenia from the first descriptions of dementia praecox to current concepts of cognitive dysmetria. Nevertheless, little is known about how to deal with them. In Alzheimer disease, cholinergic deficit is found and...

  • Dementia in Parkinson's disease. Korczyn, Amos D. // Journal of Neurology;Sep2001 Supplement 3, Vol. 248, pIII1 

    Advanced Parkinson's disease (PD) is frequently associated with dementia. The pathogenesis of this dementia is complex, related to deficiency of several biogenic amines and cortical Lewy body deposition, as well as co-existent age-related brain changes, both of the Alzheimer's type and vascular....

  • Dementia in Parkinson's disease. Martí, Maria J.; Tolosa, Eduardo; De La Cerda, Andres // Journal of Neurology;Sep2007, Vol. 254 Issue S5, p41 

    Dementia is a frequent complication of Parkinson's disease (PD), usually occurring late in the course of the illness. Clinically, dementia in PD often is characterized by an insidious onset and slowly progressive cognitive decline, with predominant dysexecutive syndrome accompanied by a variety...

  • Spotlight on Parkinson’s Disease: From a better understanding of fluctuating levodopa responses and the mechanisms of subthalamic nucleus stimulation to a better assessment of subcortical dementia. Strupp, Michael // Journal of Neurology;Dec2003, Vol. 250 Issue 12, p1513 

    The article presents information about parkinson's disease (PD). It highlights the diseases from a better understanding of fluctuating levodopa responses and the mechanisms of subthalamic nucleus stimulation to a better assessment of subcortical dementia. PD is the second most common...

  • Causes and consequences of cerebral small vessel disease. The RUN DMC study: a prospective cohort study. Study rationale and protocol. van Norden, Anouk G. W.; de Laat, Karlijn F.; Gons, Rob A. R.; van Uden, Inge W. M.; van Dijk, Ewoud J.; van Oudheusden, Lucas J. B.; Esselink, Rianne A. J.; Bloem, Bastiaan R.; van Engelen, Baziel G. M.; Zwarts, Machiel J.; Tendolkar, Indira; Olde-Rikkert, Marcel G.; van der Vlugt, Maureen J.; Zwiers, Marcel P.; Norris, David G.; de Leeuw, Frank-Erik // BMC Neurology;2011, Vol. 11 Issue 1, p29 

    Background: Cerebral small vessel disease (SVD) is a frequent finding on CT and MRI scans of elderly people and is related to vascular risk factors and cognitive and motor impairment, ultimately leading to dementia or parkinsonism in some. In general, the relations are weak, and not all subjects...

  • Parkinson's Disease Dementia – A First Step? Press, Daniel Z. // New England Journal of Medicine;12/9/2004, Vol. 351 Issue 24, p2547 

    This article presents an editorial on Parkinson's Disease Dementia. The author writes that if dementia sets in before a decline in motor skills, that the symptoms of diffuse Lewy-body disease are met. The author discusses the risks that come with Parkinson's Disease Dementia, which includes...

  • The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. Werber, E. A.; Rabey, J. M. // Journal of Neural Transmission;Nov2001, Vol. 108 Issue 11, p1319 

    Summary. Patients suffering from Parkinson's disease (PD), often develop dementia (PDD). Their brain histology reveals Alzheimer's disease (AD) like changes and decreased cholin-acetyl transferase (ChAT) activity, in addition to typical PD changes. This cholinergic deficiency has been related to...

  • The pattern of cortical atrophy in Parkinson's disease with mild cognitive impairment according to the timing of cognitive dysfunction. Lee, Ji; Cho, Kyoo; Kim, Myonghwan; Sohn, Young; Lee, Phil // Journal of Neurology;Mar2012, Vol. 259 Issue 3, p469 

    The density of Lewy bodies or the concurrent β-amyloid pathology would act as modulators in the relative timing of dementia during the course of Parkinson's disease. Depending on the temporal relationship between the onset of parkinsonism and that of cognitive impairment, patients with...

  • Subjective poor sleep quality in Chinese patients with Parkinson's disease without dementia. Li Zhang; Jingde Dong; Weiguo Liu; Yingdong Zhang // Journal of Biomedical Research;Jul2013, Vol. 27 Issue 4, p291 

    Parkinson's disease (PD) is a common progressive neurological disorder and is composed of motor and nonmotor symptoms. Sleep disturbances are frequent problems for patients with PD. The relationship between sleep disturbances with Hoehn and Yahr (H&Y) staging have been demonstrated. However, the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics